<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04929158</url>
  </required_header>
  <id_info>
    <org_study_id>clinical 2020-401</org_study_id>
    <nct_id>NCT04929158</nct_id>
  </id_info>
  <brief_title>Comparison of Clinical Outcomes of IVUS -Guided and Angiography-guided PCI in Patients With Acute STEMI</brief_title>
  <official_title>Comparison of Clinical Outcomes of Intravascular Ultrasound (IVUS) -Guided and Angiography-Guided Primary Percutaneous Intervention (PCI) in Patients With Acute ST Segment Elevated Myocardial Infarction (STEMI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second People's Hospital of Hangzhou City in Zhejiang Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Tongxiang City in Zhejiang Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The People's Hospital of Quzhou City in Zhejiang Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Ningbo City in Zhejiang Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Province People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Taizhou City in Zhejiang Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Central Hospital of Huzhou City in Zhejiang Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The People's Hospital of Changxing City in Zhejiang Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the long-term clinical outcomes of IVUS-guided vs angiography-guided PCI in&#xD;
      patients with acute STEMI&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, multicenter, randomized controlled trial, led by the second&#xD;
      hospital affiliated to zhejiang university school of medicine, A total of 10 hospitals in&#xD;
      zhejiang province interventional cardiovascular center to participate in, plan to recruit 200&#xD;
      STEMI patients.&#xD;
&#xD;
      Subjects according to the proportion of 1:1 were randomly allocated to two treatment&#xD;
      groups.(Experimental group (IVUS) steering group or control group (imaging) steering group.)&#xD;
      Plan 10 centers in 200 men and women aged 18 and older patients, according to the American&#xD;
      heart association and the United States The college of cardiology interventional treatment&#xD;
      guidelines for the participants.&#xD;
&#xD;
      Each center recruiting number does not exceed 40% of the total plan recruitment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE rate at 12 months</measure>
    <time_frame>up to 12 months</time_frame>
    <description>major adverse cardiac event (MACE) rate at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence of myocardial infarction(including : Myocardialinfarction, Q-wave and non-Q-wave )at 12 months</measure>
    <time_frame>up to 12 months</time_frame>
    <description>defined as cardiac death, myocardial infarction at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TVR(Target Vessel Revascularization) at 12 months</measure>
    <time_frame>up to 12 months</time_frame>
    <description>defined as cardiac death, myocardial infarction at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiovascular Events(2-3 years annual assessment)</measure>
    <time_frame>3 years</time_frame>
    <description>MACE(including:Recurrence of angina pectoris, Acute Myocardial Infarction, Severe Arrhythmia, Heart Failure, Coronary Heart Disease Death&#xD;
)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLR(3 years to evaluate each year)</measure>
    <time_frame>3 years</time_frame>
    <description>TLR=Target Lesion Reascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLF(3 years to evaluate each year)</measure>
    <time_frame>3 years</time_frame>
    <description>TLF=Target Lesion Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TVR(3 years to evaluate each year)</measure>
    <time_frame>3 years</time_frame>
    <description>TVR=Target Vessels Reascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TVF(3 years to evaluate each year)</measure>
    <time_frame>3 years</time_frame>
    <description>TVF=Target Vessels Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MI (including:Q-wave and non-Q-wave)</measure>
    <time_frame>3 years</time_frame>
    <description>Myocardialinfarction, Q-wave and non-Q-wave</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>3 years</time_frame>
    <description>All-cause death (including: cardiac and non cardiac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>3 years</time_frame>
    <description>Stent Thrombosis (including:Sure/May stent thrombosis)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Intravascular Ultrasound (IVUS) -guided Primary Percutaneous Intervention (PCI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravascular ultrasound guided surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiography-Guided Primary Percutaneous Intervention (PCI)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Angiography-Guided guided surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravascular Ultrasound (IVUS) -guided Primary Percutaneous Intervention (PCI)</intervention_name>
    <description>Preoperative criminal vascular assessment； The criminal vascular assessment after surgery</description>
    <arm_group_label>Intravascular Ultrasound (IVUS) -guided Primary Percutaneous Intervention (PCI)</arm_group_label>
    <other_name>Boston Scientific，Opticross</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Clinical Inclusion (CI) Criteria: CI. Age &gt; 18 years C2. Onset of STEMI &gt; 30 minutes, but&#xD;
        &lt; 12 hours C3. ST segment elevation in at least 2 contiguous leads of≥ 1mm or newly&#xD;
        developed LBBB on ECG C4. Willing and able to provide informed consent&#xD;
&#xD;
          -  Angiographic Inclusion (AI) Criteria (visual estimate) AI1. Having at least one&#xD;
             infarct-related coronary artery of which&#xD;
&#xD;
          -  the Culprit lesion is suitable for stenting&#xD;
&#xD;
          -  the reference diameter of culprit vessel is ≥ 2.5 mm but ≤ 4 mm&#xD;
&#xD;
          -  the TIMI flow is ≤ 1 in culprit lesion segment prior to guide wire crossing AI2. No&#xD;
             excessive tortuosity and calcification in the culprit lesion segment that allowing&#xD;
             stent implantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical Exclusion (CE) Criteria CE1. Contraindicating to any concomitant study&#xD;
             medications CE2. Having cardiogenic shock with hemodynamic instability CE3. A history&#xD;
             of bleeding diathesis or known coagulopathy CE4. A history of cerebrovascular accident&#xD;
             (CVA) or transient ischemic attack (TIA) within the past 6 months; or a history of&#xD;
             intracranial tumor, aneurysm or arteriovenous malformations; or a history of active&#xD;
             peptic ulcer or active gastrointestinal (GI) bleeding within the past 2 months; or&#xD;
             planned major procedure within 6 weeks; or known platelet count &lt; 100,000 /mm3 or Hb &lt;&#xD;
             10 g/dL CE5. Planned surgery which may cause discontinuation of ADP-receptor&#xD;
             antagonist CE6. Other serious illness (e.g., cancer) that may reduce life expectancy&#xD;
             to less than 1 year CE7. Repeated MI within 7 days of hospitalization for acute MI&#xD;
&#xD;
          -  Angiographic Exclusion (AE) Criteria (visual estimate) AE1. Bifurcated lesion unable&#xD;
             to identify the culprit lesion AE2. The culprit lesion is located in the left main&#xD;
             artery. AE3. Diffusive lesions without distinguishable culprit lesion AE4. Previous&#xD;
             stent implantation in the culprit lesion segment or STEMI caused by stent thrombosis&#xD;
             AE5. Likely CABG procedure within 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianan Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liang Dong</last_name>
    <phone>13858188861</phone>
    <email>gemsangel@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, School of Medicine at Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Dong, PhD</last_name>
      <phone>+13858188861</phone>
      <email>gemsangel@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianan Wang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ST Elevation Myocardial Infarction，</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT04929158/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 25, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT04929158/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

